Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Rasmussen, Thomas A ^a   Jensen, Danny ^a   Tolstrup, Martin ^a   Nielsen, Ulla S ^a   Erlandsen, Erland J ^b   Birn, Henrik ^a   Østergaard, Lars ^a   Langdahl, Bente L ^a   Laursen, Alex L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b VIBORG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ALBUMIN; ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; CREATININE; CYSTATIN C; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOCALCIN; OSTEOPROTEGERIN; PROCOLLAGEN N PROTEINASE; TENOFOVIR; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ABACAVIR, LAMIVUDINE DRUG COMBINATION; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL MARKER; DEOXYCYTIDINE; DRUG DERIVATIVE; EMTRICITABINE; LAMIVUDINE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ARTICLE; BONE DENSITY; BONE DISEASE; BONE MASS; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LUMBAR SPINE; MALE; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; BLOOD; BONE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; KIDNEY; KIDNEY FUNCTION TEST; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME; URINE;

ADENINE; ADULT; ALKALINE PHOSPHATASE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; CREATININE; CYSTATIN C; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; LAMIVUDINE; MALE; MIDDLE AGED; OSTEOCALCIN; PHOSPHONIC ACIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84859048370     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032445     Document Type: Article

References (45)

1. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, et al. (2007) Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 146: 87-95.
2. Society EAC (2009) Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe, Version 5-4.
3. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, et al. (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300: 555-570.
4. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA: the journal of the American Medical Association 304: 321-333.
5. Brown TT, Qaqish RB, (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20: 2165-2174.
6. Young B, Dao CN, Buchacz K, Baker R, Brooks JT, (2011) Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 52: 1061-1068.
7. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292: 191-201.
8. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, et al. (2009) Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. Journal of acquired immune deficiency syndromes 51: 554-561.
9. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, et al. (2009) Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 23: 817-824.
10. van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, et al. (2009) First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 23: 1367-1376.
11. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, et al. (2010) Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 51: 963-972.
12. Hansen AB, Obel N, Nielsen H, Pedersen C, Gerstoft J, (2011) Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Med 12: 157-165.
13. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, et al. (2011) Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: aids clinical trials group A5224s, a substudy of ACTG A5202. The Journal of infectious diseases 203: 1791-1801.
14. Martin A, Bloch M, Amin J, Baker D, Cooper DA, et al. (2009) Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis 49: 1591-1601.
15. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, et al. (2003) Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 36: 1070-1073.
16. Peyriere H, Reynes J, Rouanet I, Daniel N, De Boever CM, et al. (2004) Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 35: 269-273.
17. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. (2006) Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. The New England journal of medicine 354: 251-260.
18. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, et al. (2010) Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 51: 496-505.
19. Smith KY, Patel P, Fine D, Bellos N, Sloan L, et al. (2009) Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 23: 1547-1556.
20. Martinez E, Arranz JA, Podzamczer D, Lonca M, Sanz J, et al. (2009) A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr 51: 290-297.
21. Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, et al. (2006) A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 20: 2043-2050.
22. Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, et al. (2010) Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. Journal of acquired immune deficiency syndromes 55: 49-57.
23. Rasmussen TA, Tolstrup M, Melchjorsen J, Frederiksen CA, Nielsen US, et al. (2011) Evaluation of Cardiovascular biomarkers In HIV-infected Patients Switching to Abacavir or Tenofovir Based Therapy. BMC infectious diseases 11: 267.
24. Szulc P, Delmas PD, (2008) Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 19: 1683-1704.
25. Leeming DJ, Alexandersen P, Karsdal MA, Qvist P, Schaller S, et al. (2006) An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. European journal of clinical pharmacology 62: 781-792.
26. Trouvin AP, Goeb V, (2010) Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging 5: 345-354.
27. Wagner D, Fahrleitner-Pammer A, (2010) Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help? Wien Med Wochenschr 160: 452-457.
28. Erlandsen EJ, Randers E, Kristensen JH, (1999) Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scandinavian journal of clinical and laboratory investigation 59: 1-8.
29. Randers E, Erlandsen EJ, Pedersen OL, Hasling C, Danielsen H, (2000) Serum cystatin C as an endogenous parameter of the renal function in patients with normal to moderately impaired kidney function. Clinical nephrology 54: 203-209.
30. Haskelberg HJJ, Amin J, et al. (2011) Lower body fat mass and lower bone formation predict greater bone loss with tenofovir in HIV-infected adults. Conference on HIV Pathogenesis, Treatment and Prevention. Rome, July 17-20.
31. Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, et al. (2009) Continuous antiretroviral therapy decreases bone mineral density. AIDS 23: 1519-1529.
32. Hoy J, (2011) Plasma markers of bone loss and bone formation decrease with intermittent antiretroviral therapy and predict change in bone mineral density. 13th International Workshop on Adverse Drus Reactions and Co-morbidities in HIV Rome, Italy Antiviral Therapy.
33. Warming L, Hassager C, Christiansen C, (2002) Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 13: 105-112.
34. van Staa TP, Leufkens HG, Cooper C, (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 13: 777-787.
35. Carr A, Hoy J, (2010) Low bone mineral density with tenofovir: does statistically significant mean clinically significant? Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 51: 973-975.
36. Mallon PW, (2010) HIV and bone mineral density. Curr Opin Infect Dis 23: 1-8.
37. Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Carlson AE, et al. (2010) Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochemical and biophysical research communications 394: 48-53.
38. Grigsby IF, Pham L, Gopalakrishnan R, Mansky LM, Mansky KC, (2010) Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts. Biochemical and biophysical research communications 391: 1324-1329.
39. Gutierrez F, Masia M, (2011) The role of HIV and antiretroviral therapy in bone disease. AIDS Rev 13: 109-118.
40. Bonjoch A, Bayes B, Riba J, Puig J, Estany C, et al. (2010) Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort. Antiviral research 88: 347-354.
41. Barraclough K, Er L, Ng F, Harris M, Montaner J, et al. (2009) A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population. Nephron Clinical practice 111: c39-48.
42. McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, et al. (2007) Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 21: 2473-2482.
43. Mondy K, Powderly WG, Claxton SA, Yarasheski KH, Royal M, et al. (2005) Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. Journal of acquired immune deficiency syndromes 38: 426-431.
44. Guaraldi G, Orlando G, Madeddu G, Vescini F, Ventura P, et al. (2004) Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials 5: 269-277.
45. Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, et al. (2007) Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab 92: 1283-1288.